What's in SamA Pharmaceutical Co., Ltd's pipeline?

SamA Pharmaceutical Co., Ltd has 9 drugs in our index: 3 marketed, 0 filed, 4 in Phase 3, 2 in Phase 2, 0 in Phase 1.

Which companies overlap with SamA Pharmaceutical Co., Ltd's portfolio?

Top competitors by shared drug class: GlaxoSmithKline, Arbutus Biopharma Corporation, Australasian Gastro-Intestinal Trials Group, Casa Sollievo della Sofferenza IRCCS, Ain Shams University.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/sama-pharmaceutical-co-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-06-10 · How we verify

SamA Pharmaceutical Co., Ltd — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

SamA Pharmaceutical Co., Ltd pipeline: 3 marketed, 0 filed, 4 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

3 marketed 0 filed 4 Phase 3 2 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Tulobuterol patch with placebo dry syrup	Tulobuterol patch with placebo dry syrup	marketed	Beta-2 adrenergic agonist (long-acting)	Beta-2 adrenergic receptor	Respiratory
PRIC	PRIC	marketed			Other
Atock Dry Syrup with placebo patch	Atock Dry Syrup with placebo patch	marketed
CITUS Dry Syrup	CITUS Dry Syrup	phase 3	Antiviral	NS5B polymerase	Infectious Diseases
Pranlukast hydrate	Pranlukast hydrate	phase 3	Leukotriene receptor antagonist	CysLT1 receptor	Respiratory
Active Comparator Control 2	Active Comparator Control 2	phase 3
Active Comparator Control 1	Active Comparator Control 1	phase 3

Therapeutic area mix

Respiratory · 2
Infectious Diseases · 1
Other · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

GlaxoSmithKline · 2 shared drug classes
Arbutus Biopharma Corporation · 1 shared drug class
Australasian Gastro-Intestinal Trials Group · 1 shared drug class
Casa Sollievo della Sofferenza IRCCS · 1 shared drug class
Ain Shams University · 1 shared drug class
Hospital Universitari Vall d'Hebron Research Institute · 1 shared drug class
Hull University Teaching Hospitals NHS Trust · 1 shared drug class
ALK-Abelló A/S · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for SamA Pharmaceutical Co., Ltd:

Cite this brief

Drug Landscape (2026). SamA Pharmaceutical Co., Ltd — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/sama-pharmaceutical-co-ltd. Accessed 2026-06-10.